

**Aaron Ambrad, M.D.**

**Ironwood Cancer and Research Centers**

**Division of Radiation Oncology**

Breast, Gynecologic, Lung, Head & Neck and Genitourinary Malignancies

**Education:**

7/2000 to 6/2004	<b>University of Arizona Health Sciences Center</b> , Tucson, AZ Chief Resident - Radiation Oncology. Graduated in June 2004
7/1999 to 6/2000	<b>University of Pittsburgh Medical Center – McKeesport</b> , McKeesport, PA Internal Medicine Internship
8/1995 to 6/1999	<b>University of Illinois College of Medicine</b> , Champaign-Urbana, IL Medical Scholars Program. M.D. conferred in May 1999
8/1994 to 6/1995	<b>University of Illinois College of Commerce</b> , Champaign-Urbana, IL Medical Scholars Program. M.B.A. conferred in May 1999
8/1989 to 6/1993	<b>Haverford College</b> , Philadelphia, PA B.A. Economics conferred in May 1993

**Professional Experience:**

November 2006 – Present	Radiation Oncologist, Ironwood Cancer & Research Centers, Scottsdale, AZ
July 2004 – November 2006	Radiation Oncologist, Northeastern Radiation Oncology, Queensbury, NY

**Activities and Honors:**

Certifications:

Board Certified in Radiation Oncology

Awards, Honors and Committees:

***PHOENIX Magazine Top Doc Award***

***Intern of the Year***, 1999 to 2000, UPMC-McKeesport

***Allie-Signal Scholar***, 1994, University of Illinois

**Professional Memberships:**

ASTRO

ARRO

ASCO

**Publications:**

Patel J., Glanzberg H., Stadheim C., **Ambrad A.A.**, and Meuillet E.J. DPIEL, a novel Akt inhibitor radiosensitizes glioblastoma cells, independently of PTEN expression. Submitted to *Can Res*.

Brandis A., Patel J., Stadheim C., **Ambrad A.A.**, Martinez J.D., and Meuillet E.J. Unraveling the role of CDK6 in the radiosensitization of glioblastoma cells. Submitted to *Oncogene*.

Stea B., Falsey R., Kislin K., Patel J., Glanzberg H., Carey S., **Ambrad, A.A.**, Meuillet E.J. and Martinez J.D. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa') *Can Lett*, 2003, Dec 8; 202(1): 43-51.

**Ambrad A.A.**, Stadheim C., Kislin K., Stea B., Martinez J.D. and Meuillet E.J. The Radiosensitization of the Human Glioblastoma Multiforme Cell Line U251 by the EGFR Inhibitor ZD1839 ('Iressa') is not due to the inhibition of the MEK1/ERK-1/2 Pathway. *Mol Can Res...*

Glanzberg H., Kislin K., Stadheim C., **Ambrad A.A.**, Stea B., Martinez J.D. and Meuillet E.J. Geldanamycin and 17-AAG Radiosensitize Human Glioblastoma Cells, *Mol Can Res*.

Kislin K., Glanzberg H., Stadheim C., **Ambrad A.A.**, Falsey R., Stea B., Martinez J.D. and Meuillet E.J. *Inhibition of Heat Shock Protein Hsp90 by the Geldanamycin Derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) Radiosensitizes Glioblastoma Multiforme*. AACR, Washington, D.C. July 11-14, 2003

Stea B., Kislin K., Stadheim C., **Ambrad A.A.**, Falsey R., Meuillet E.J. and Martinez J.D. *ZD1839 ('Iressa') Radiosensitizes Glioblastoma Multiforme by Altering Patterns of Genes Expression in a Time Dependent Manner*. AACR, Washington, D.C. July 11-14, 2003

**Ambrad A.A.**, Stea B., Martinez J., Falsey R., Kislin K., and Meuillet E.J. *Mechanism of the Radiosensitization of Glioblastoma Multiforme by the EGFR Tyrosine Kinase Inhibitor, ZD1839 ('Iressa')*. Society of Neuro-Oncology Meeting, San Diego, CA. Nov. 21-24, 2002

**Ambrad A.A.**, Stea B., Martinez J., Mahadevan D., Falsey R., Kislin K., and Meuillet E.J. *ZD1839 ('Iressa') an EGFR Tyrosine Kinase Inhibitor Radiosensitizes Glioblastoma Multiforme by Inhibition of a Cell Survival Pathway*. 44<sup>th</sup> Annual ASTRO Meeting, New Orleans, LA. October 5-10, 2002

Kenneth M. Algazy, Mitchell Machtay, Joseph S. Friedberg, **Aaron Ambrad**, Stephen M. Hahn, David I. Rosenthal, James P. Stevenson, Joseph Treat, Eli Glatstein, Larry R. Kaiser: *Neoadjuvant Chemoradiotherapy Prior to Surgery for Stage IIIA Non-Small Cell Lung Carcinoma (NSCLC): A Nonrandomized Comparison of Carboplatin/Paclitaxel to Etoposide/Cisplatin*. 35<sup>th</sup> Annual ASCO Meeting, Atlanta, GA. May 15-18, 1999

Krisch R.E., Ayene S.I., **Ambrad A.A.**, Koch C.J.: *Mechanisms of double-strand break formation by secondary glycerol radicals in irradiated SV40 DNA*. 10<sup>th</sup> International Congress of Radiation Research, Wurzburg, Germany. Aug. 27-Sept. 1, 1995

Ayene S.I., Koch C.J., **Ambrad A.A.**, Krisch R.E.: *Modification of oxygen effect on DNA strand break formation by scavenging environment*. 42<sup>nd</sup> Annual Meeting of the Radiation Research Society, Nashville, TN. April 29-May 4, 1994

Ayene S.I., Koch C.J., **Ambrad A.A.**, Krisch R.E.: *Interaction of thiol and non-thiol scavengers in the modification of radiation-induced DNA damage*. 18<sup>th</sup> LH Gray Conference, University of Bath, England. April 10-14, 1994

**Selected Presentations**

ZD1839 ('Iressa') an EGFR Tyrosine Kinase Inhibitor Radiosensitizes Glioblastoma Multiforme by Inhibition of a Cell Survival Pathway: Oral presentation. 44<sup>th</sup> Annual ASTRO Meeting, New Orleans, LA. October 8, 2002

**Research Trials:**

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

**Other Activities:**

During his free time, Dr. Ambrad enjoys hiking, golf, tennis, travel, live music and good eats!